Consecutive magnetic resonance imaging during brachytherapy for cervical carcinoma: predictive value of volume measurements with respect to persistent disease and prognosis

J. E. Mongula*, B. F. M. Slangen, D. M. J. Lambregts, F. Cellini, F. C. H. Bakers, L. C. H. W. Lutgens, T. Van Gorp, A. J. Kruse, R. F. P. M. Kruitwagen, R. G. H. Beets-Tan

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)


Background: Cervical cancer is associated with a high yearly mortality. The presence of persistent disease after radiotherapy is a significant predictor of patient survival. The aim of our study was to assess if tumor volume regression measured with MR imaging at the time of brachytherapy can discriminate between patients who eventually will achieve a complete response to radiotherapy from those who will not. The second objective was to evaluate whether tumor volume regression predicts overall treatment failure. Methods: MRI was evaluated quantitatively in 35 patients; by means of tumor volumetry on T2-weighted MR images before treatment, at the first BCT application, and at the final BCT. The MR images were independently analyzed by two investigators. As a reference standard histopathologic confirmation of residual tumor and/or clinical exam during follow-up >1 year were used. Area under the curve were compared, P-values 9.4 cm(3) at final BCT and tumor volume regression 2.8 cm(3) at final BCT was associated with overall treatment failure (p <0.03). Conclusion: Our study shows that volume analysis during BCT is a predictive tool for local tumor response and overall treatment outcome. The potential of local response assessment to identify patients at high risk of overall treatment failure is promising.
Original languageEnglish
Article number252
JournalRadiation Oncology
Publication statusPublished - 8 Dec 2015


  • Cervical carcinoma
  • Brachytherapy
  • Magnetic resonance imaging
  • Tumor volume
  • Predictive tool

Cite this